Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., subject to its regulatory approval.
Zircaix targets carbonic anhydrase IX (or CAIX), a protein expressed on the surface of clear cell renal cell carcinoma and several other tumor types and is administered through an intravenous injection in the arm prior to diagnostic PET imaging. In a recent phase III trial, the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease.
If approved, Zircaix will be the first targeted PET agent specifically for kidney cancer to be commercially available in the U.S., the company noted.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
